Abstract
The availability of safe and effective endoscopic techniques has caused a major shift in the management of Barrett’s associated dysplasia and early cancer from primarily surgical to endoscopic therapy. Prior to contemplating endoscopic therapy, careful selection of patients is essential and best served by evaluation with multidisciplinary team at specialized centers. This requires detailed examination of Barrett’s segment with removal of nodules or suspicious areas with endoscopic mucosal resection and expert confirmation of dysplasia by at least two gastrointestinal pathologists. This should be followed by eradication of remaining Barrett’s segment with ablation and ongoing vigilant surveillance as recurrences have been reported. Endoscopic therapy is considered in Barrett’s associated intramucosal cancer, Barrett’s esophagus with high-grade dysplasia, confirmed cases of low-grade dysplasia, and rare instances of non-dysplastic Barrett’s such as those with long segment and family history as complete eradication of Barrett’s esophagus is associated with marked reduction in cancer risk. Palliative therapy with photodynamic therapy or cryotherapy can be considered in selected cases of inoperable cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berenson MM, Johnson TD, Markowitz NR et al (1993) Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium. Gastroenterology 104:1686–1691
Pech O, Behrens A, May A et al (2008) Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 57:1200–1206
Bergman JJGHM, Fockens P (2006) Ablating Barrett’s metaplastic epithelium: are the techniques ready for clinical use? Gut 55(9):1222–1223
Shaheen NJ, Sharma P, Overholt BF et al (2009) Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 360:2277–2288
Shaheen NJ, Overholt BF, Sampliner RE et al (2011) Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 141:460–468
Phoa KN, van Vilsteren FGI, Weusten LAM et al (2014) Radiofrequency ablation vs endoscopic surveillance for patients with Barrett Esophagus and low-grade dysplasia. A randomized clinical trial. JAMA 311(12):1209–1217
Shaheen NJ, Greenwald BD, Peery AF et al (2010) Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc 71:680–685
Gosain S, Mercer K, Twaddell WS et al (2013) Liquid nitrogen spray cryotherapy in Barrett’s esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc 78(2):260–265
Greenwald BD, Dumot JA, Abrams JA et al (2010) Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc 71(4):686–693
Canto MI, Gorospe EC, Shin EJ et al (2009) Carbon dioxide (CO2) Cryotherapy is a safe and effective treatment of Barrett’s Esophagus (BE) with HGD/Intramucosal Carcinoma. Gastrointest Endosc 69:AB341
Greenwald BD, Dumot JA, Horwhat D, Lightdale CJ, Abrams JA (2010) Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus 23:13–19
Dumot JA, Vargo JJ, Falk GW et al (2009) An open-label, prospective trial of cryospray ablation for Barrett’s esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 70:635–644
Overholt BF, Lightdale CJ, Wang KK et al (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62(4):488–498
Overholt BF, Wang KK, Burdick JS et al (2007) Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc 66(3):460–468
Pacifico RJ, Wang KK, Wongkeesong LM et al (2003) Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus. Clin Gastroenterol Hepatol 1:252–257
Prasad GA, Wu TT, Wigle DA et al (2009) Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology 137:815–823
Grade AJ, Shah IA, Medlin SM et al (1999) The efficacy and safety of argon plasma coagulation therapy in Barrett’s esophagus. Gastrointest Endosc 50:18–22
Lewis CJ, Caplin S, Armstrong G et al (2003) Argon Beam Plasma Coagulation as an ablative therapy for high grade dysplasia in Barrett’s Oesophagus. Clin Gastroenterol Hepatol 1(4):258–263
Akhtar K, Byrne JP, Bancewicz J et al (2000) Argon Beam Plasma Coagulation in the management of cancers of the esophagus and stomach. Surg Endoscopy 14:1127–1130
Sampliner RE, Faigel D, Fennerty MB et al (2001) Effective and safe endoscopic reversal of nondysplastic Barrett’s esophagus with thermal electrocoagulation combined with high dose acid suppression: a multicenter study. Gastrointest Endosc 53:554–558
Sharma P, Bhattacharyya A, Garewal HS et al (1999) Durability of new squamous epithelium after endoscopic reversal of Barrett’s Esophagus. Gastrointest Endosc 50:159–164
Sharma P, Jaffe PE, Bhattacharyya A et al (1999) Laser and multipolar electrocoagulation ablation of early Barrett’s adenocarcinoma. Gastrointest Endosc 49:442–446
Wu J, Pan Y, Wang T et al (2014) Endotherapy versus surgery for early neoplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc 79(2):233–241
Titi M, Overhiser A, Ulusarac O et al (2012) Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett’s esophagus. Gastroenterology 143:564–566
Gray NA, Odze RD, Spechler SJ (2011) Buried metaplasia after endoscopic ablation of Barrett’s esophagus: a systematic review. Am J Gastroenterol 106:1899–1908
Gupta N, Mathur SC, Dumot JA et al (2012) Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett’s esophagus? Gastrointest Endosc 75:11–18
Anders M, Lucks Y, El-Masry MA et al (2014) Subsquamous extension of intestinal metaplasia is detected in 98% of cases of neoplastic Barrett’s esophagus [published online July 23, 2013]. Clin Gastroenterol Hepatol 12(3):405–410. doi:http://dx.doi.org/10.1016/j.cgh.2013.07.013
Chennat J, Ross AS, Konda VJ et al (2009) Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management. Gastrointest Endosc 70:417–421
Gupta M, Iyer PG, Lutzke L et al (2013) Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 145:79–86
Pasricha S, Bulsiewicz WJ, Hathorn K et al (2014) Durability and predictors of successful radiofrequency ablation for Barrett’s Esophagus. Clin Gastroenterol Hepatol 12(11):1840–1847
Fitzgerald RC, di Pietro M, Ragunath K et al (2014) British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 63:7–42
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Thota, P.N. (2017). Ablation Techniques for Barrett’s Esophagus and Dysplasia. In: Giacopuzzi, S., Zanoni, A., de Manzoni, G. (eds) Adenocarcinoma of the Esophagogastric Junction. Springer, Cham. https://doi.org/10.1007/978-3-319-28776-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-28776-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28774-4
Online ISBN: 978-3-319-28776-8
eBook Packages: MedicineMedicine (R0)